CDK6 and breast cancer: BC-3 cells expressing RelA-DD showed resistance to Palbociclib, whereas addition of uridine further conferred drug resistance (Fig. S7E), emphasizing the metabolic functions of CDK6 in BC-3 to support cell proliferation.